[How to manage abdominal hernia on peritoneal dialysis?]

Comment prendre en charge une hernie abdominale en dialyse péritonéale ?
Dialyse péritonéale Hernia Hernies Parietal prothesis Peritoneal dialysis Prothèse pariétale

Journal

Nephrologie & therapeutique
ISSN: 1872-9177
Titre abrégé: Nephrol Ther
Pays: France
ID NLM: 101248950

Informations de publication

Date de publication:
May 2020
Historique:
received: 28 06 2019
accepted: 17 07 2019
pubmed: 1 2 2020
medline: 29 10 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

Abdominal hernias are a frequent complication in peritoneal dialysis, representing up to 60.4% of anatomical complications. Their prevalence varies between 7 and 27.5%. Established risk factors are male gender, an older age, multiparity, a low body mass index and a paramedian approach for the catheter insertion. Polykystic renal disease and the intra-peritoneal volume are controversial risk factors. The diagnosis is mainly clinical, though peritoneography imaging can be useful in difficult cases. Hernia's complications, of strangulation, incarceration, bowel occlusion and peritonitis; can be very serious, leading to technique failure and may result in death. The complication risk varies from 4 to 20% in the literature review. There are no guidelines regarding hernia's prevention or treatment. A surgical repair is recommended, by implementing a synthetic prothesis with an inguinal approach for inguinal and femoral hernias, with a simple stitch or a bioprothesis for ombilical hernias. The management of peritoneal dialysis after hernia repair is not codified. After an initial 48h interruption, an intermittent peritoneal dialysis program using low volume seems efficient at low risk, preventing a temporary transfer to haemodialysis.

Identifiants

pubmed: 32001162
pii: S1769-7255(19)30563-2
doi: 10.1016/j.nephro.2019.07.331
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

164-170

Informations de copyright

Copyright © 2019 Société francophone de néphrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Annabel Boyer (A)

Centre universitaire des maladies rénales, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France; U1086 Inserm-Anticipe-centre régional de lutte contre le cancer François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France. Electronic address: annabel.boyer@wanadoo.fr.

Cécile Bonnamy (C)

Service de chirurgie digestive, centre hospitalier Aunay-Bayeux, 13, rue de Nesmond, 14400 Bayeux cedex, France.

Antoine Lanot (A)

Centre universitaire des maladies rénales, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France; U1086 Inserm-Anticipe-centre régional de lutte contre le cancer François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France; UFR de médecine, Normandie Université, Unicaen, 2, rue des Rochambelles, 14032 Caen cedex, France.

Sonia Guillouet (S)

Centre universitaire des maladies rénales, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France; U1086 Inserm-Anticipe-centre régional de lutte contre le cancer François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France.

Clémence Béchade (C)

Centre universitaire des maladies rénales, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France; U1086 Inserm-Anticipe-centre régional de lutte contre le cancer François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France; UFR de médecine, Normandie Université, Unicaen, 2, rue des Rochambelles, 14032 Caen cedex, France.

Marie Recorbet (M)

Centre universitaire des maladies rénales, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France; UFR de médecine, Normandie Université, Unicaen, 2, rue des Rochambelles, 14032 Caen cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH